MRS AD Study.

No registrations found.

Ethical review	Positive opinion
Status	Recruitment stopped
Health condition type	-
Study type	Interventional

Summary

ID

NL-OMON23328

Source Nationaal Trial Register

Brief title MRS AD study

Health condition

Alzheimer; ⁻s Disease

Sponsors and support

Primary sponsor: Danone Research "C Centre for Specialised Nutrition **Source(s) of monetary or material Support:** Danone Research "C Centre for Specialised Nutrition

Intervention

Outcome measures

Primary outcome

1. The main 31P-MRS outcome parameters are the total level of Phosphomonoesters (PME), total level of Phosphodiesters (PDE), and the ratio between PME and PDE;

2. 1H-MRS outcome parameters: Absolute and relative brain tissue levels of several metabolites.

Secondary outcome

Blood parameters: Nutritional blood parameters.

Study description

Background summary

In this trial the effect of intervention with a Medical Food on phospholipid metabolism in the brain will be compared with a control product in subjects with mild Alzheimer's disease dementia. The study is performed in 1 centre in the Netherlands.

Study objective

A 4 week intervention with the study product will affect MRS detectable brain metabolites related to phospholipid metabolism.

Study design

Baseline (day 0);

Visit 2 (day 28).

Intervention

Duration of intervention: 4 weeks.

Intervention group:

All participants in the intervention group will receive daily 125 ml of Souvenaid®. Souvenaid® is a 125ml (125kcal) once-a-day drink that contains the specific nutrient combination FortasynTM Connect.

Control group:

All participants in the control group will receive daily 125 ml of a control product. The control product is iso-caloric, similar in flavour, appearance, and composition without FortasynTM Connect.

Contacts

Public Danone Research - Centre for Specialised Nutrition PO Box 7005 Rico L. Wieggers Wageningen 6700 CA The Netherlands +31 (0)317 467 800/+31 (0)646 237 293 Scientific Danone Research - Centre for Specialised Nutrition PO Box 7005 Rico L. Wieggers Wageningen 6700 CA The Netherlands +31 (0)317 467 800/+31 (0)646 237 293

Eligibility criteria

Inclusion criteria

Main inclusion criteria:

1. Diagnosis of probable or possible AD with evidence of the pathophysiological process according to the recently revised criteria;

2. MMSE score \geq 20;

3. MRI or CT scan within two years before baseline showing no evidence of any other potential cause of dementia other than AD;

- 4. Age \geq 50 years;
- 5. Availability of responsible caregiver;
- 6. Written informed consent of patient and caregiver.

Exclusion criteria

Main exclusion criteria:

- 1. Diagnosis of significant neurological and/or psychiatric disease other than AD;
- 2. History or expected need during the study of approved anti-AD medication;
- 3. Geriatric Depression Scale > 6 on 15-item scale;
- 4. Hachinski Ischemia Scale score > 5;
- 5. Use within two months prior to baseline of:
- A. Omega-3 fatty acid containing supplements;
- B. Oily fish (when consumed more than twice a week).
- 6. Alcohol or drug abuse in opinion of the investigator;
- 7. Contraindications to magnetic resonance imaging (MRI).

Study design

Design

Study type:	Interventional
Intervention model:	Parallel
Allocation:	Randomized controlled trial
Masking:	Double blinded (masking used)
Control:	Placebo

Recruitment

NL	
Recruitment status:	Recruitment stopped
Start date (anticipated):	01-04-2012
Enrollment:	30
Туре:	Actual

Ethics review

Positive opinion

Date: Application type:

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register	ID
NTR-new	NL3195
NTR-old	NTR3346
Other	Danone : Alz.1.C/H
ISRCTN	ISRCTN wordt niet meer aangevraagd.

Study results

Summary results

Results published in 'Alzheimer's Research & Therapy', website: https://doi.org/10.1186/s13195-017-0286-2